TouchIMMUNOLOGY got the opportunity to catch up with Professor Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss the final recommendations from the DORIS taskforce in defining remission in systemic lupus erythematosus.
The abstract ‘The 2021 DORIS Definition Of Remission In SLE – Final Recommendations from an International Task Force.‘ (OP0296), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- What were the key recommendations of the Taskforce for systemic lupus erythematosus (SLE)? (0:15)
- What is the 2021 DORIS definition of remission in SLE and how should it be used? (2:41)
Disclosures: Ronald Van Vollenhoven discloses receiving research support (institutional grants): BMS, GSK, Lilly, UCB; support for educational programs (institutional grants): Pfizer, Roche; consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier, UCB; speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
